The BNP-PL is a multicenter, observational study in which patients are prospectively followed
in order to investigate clinical course and management of pulmonary hypertension in Poland.
All patients diagnosed with pulmonary arterial hypertension and chronic thromboembolic
pulmonary hypertension confirmed in right heart catheterization, will be eligible to
participate in the study.
Right heart failure is the main cause of morbi-mortality in patients with pulmonary
hypertension (PH), including patients of chronic thrombo-embolic pulmonary hypertension
(CTEPH) or pulmonary arterial hypertension (PAH) etiologies. Endarterectomy is an effective
treatment for patients with CTEPH to lower pulmonary pressure. Evidence of postoperative
right heart remodeling are contrasted according to the studies and determinants of right
heart failure are still unclear. Similarly, few evidence exists on right ventricular
remodeling after bilateral lung transplantation for patients with pulmonary arterial
hypertension (PAH). Recent...
Physiological cardiovascular stress test plays a crucial role in the assessment of patients
with suspected heart disease. There are several methods of cardiac physiological stress tests
and each of them offer varied insight into cardiac physiological adaptation: passive leg
raise, intra-venous fluid challenge, pharmacological stressors and physical exercise stress
test. Echocardiography, which is the mainstay for the non-invasive rest/stress assessment of
the left ventricular (LV) haemodynamics has several limitations. Novel methods of CMR imaging
allow to map intra-cardiac flow in three-dimension using novel flow acquisitions. These...
The aim of the study is to determine relevant morphologic parameters of the lung vasculature
for the differentiation between different groups of patients with pulmonary hypertension (PH)
by thoracic computer tomography (CT). In this pilot study patients undergoing right heart
catheterization will be investigated by thoracic CT and special software to determine
The investigators expect that using this non-invasive method, parameters relevant for the
differentiation of the patients with PH can be determined.
To identify epigenetic-sensitive modifications and novel biomarkers linked to pathogenesis of
pulmonary arterial hypertension (PAH), we will perform the first study analyzing
differentially-methylated regions (DMRs) in circulating T cells (CD04+ and CD08+) isolated
from peripheral blood of patients undergoing right heart catheterization. Moreover, we will
perform RNA deep sequencing on lung tissue biopsies to validate if DNA methylation signatures
in circulating T cells could reflect perturbations of gene expression in lung tissues.
Pulmonary embolism, or clots blocking the blood vessels of the lungs, is a common clinical
condition requiring treatment with blood thinners. In most patients, recovery is complete. A
small proportion of patients, however, develop complications (high blood pressure in the lung
circulation, i.e. pulmonary hypertension). Persisting breathlessness during activity is a
common symptom in many of these patients and leads to a reduced ability to engage in daily
physical activity. The reason for this activity-related breathlessness remains uncertain and
is the main question of the proposed study. Using new sophisticated technology, the
The purposes of this study are (I), to evaluate various screening methods for their ability
to predict and to confirm Pulmonary Hypertension (PH) in scleroderma patients, and (II) to
evaluate the incidence of PH (i.e. the number of new cases per year) in scleroderma patients.
The purpose of this randomized, placebo-controlled double-blind trial is to evaluate the
effect of acetazolamide on right heart function at rest in lowlanders with chronic
obstructive pulmonary disease (COPD) traveling to high altitude (HA) and developing early
signs of altitude-illness.
The purpose of this study is to evaluate the effect of a parenteral emulsion containing n-3
long-chain polyunsaturated fatty acids (LC-PUFA) in fish oil on clinical outcomes, markers of
inflammation and oxidative stress, and pain in neonates with persistent pulmonary
hypertension of the newborn (PPHN) compared with those who receive an emulsion containing soy
oil and medium-chain triglycerides (MCT) without n-3 LC-PUFA.
Chronic pulmonary hypertension (PH) is associated with impaired exercise capacity, quality of
life and right ventricular function.The disease is characterized by an increase of pulmonary
vascular resistance and pulmonary arterial pressure, leading to right heart insufficiency. In
later stages of the disease, the right heart is not able to further increase right
ventricular contractility (cardiac index) during exercise. Within the last decade, new
disease-targeted medical therapies have been approved for treatment of pulmonary arterial
hypertension (PAH). Sequential and upfront combinations of these agents have shown to further